Health Care·Pharmaceuticals·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.73 | N/A | +23.10% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.73 | N/A | +23.10% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting operational efficiencies. However, they did not provide specific revenue figures or future guidance.
We are pleased with our EPS performance this quarter.
While we did not provide specific revenue figures, we remain focused on our long-term growth strategy.
Phibro Animal Health reported a strong EPS performance, exceeding expectations by over 23%. However, the stock reacted negatively, declining by 2.28% on the day. The lack of revenue figures and future guidance may have contributed to investor uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025